Nanoparticle-mediated Expression of a Wnt Pathway Inhibitor Ameliorates Ocular Neovascularization

Overview

Journal Arterioscler Thromb Vasc Biol

Date 2015 Feb 7

PMID 25657312

Citations 23

Authors

Zhongxiao Wang

Rui Cheng

Kyungwon Lee

Puneet Tyagi

Lexi Ding

Uday B Kompella

Jing Chen

Xun Xu

Jian-Xing Ma

Affiliations

Soon will be listed here.

Abstract

Objective: The deficiency of very low-density lipoprotein receptor resulted in Wnt signaling activation and neovascularization in the retina. The present study sought to determine whether the very low-density lipoprotein receptor extracellular domain (VLN) is responsible for the inhibition of Wnt signaling in ocular tissues.

Approach And Results: A plasmid expressing the soluble VLN was encapsulated with poly(lactide-co-glycolide acid) to form VLN nanoparticles (VLN-NP). Nanoparticles containing a plasmid expressing the low-density lipoprotein receptor extracellular domain nanoparticle were used as negative control. MTT, modified Boyden chamber, and Matrigel (™) assays were used to evaluate the inhibitory effect of VLN-NP on Wnt3a-stimulated endothelial cell proliferation, migration, and tube formation. Vldlr(-/-) mice, oxygen-induced retinopathy, and alkali burn-induced corneal neovascularization models were used to evaluate the effect of VLN-NP on ocular neovascularization. Wnt reporter mice (BAT-gal), Western blotting, and luciferase assay were used to evaluate Wnt pathway activity. Our results showed that VLN-NP specifically inhibited Wnt3a-induced endothelial cell proliferation, migration, and tube formation. Intravitreal injection of VLN-NP inhibited abnormal neovascularization in Vldlr(-/-), oxygen-induced retinopathy, and alkali burn-induced corneal neovascularization models, compared with low-density lipoprotein receptor extracellular domain nanoparticle. VLN-NP significantly inhibited the phosphorylation of low-density lipoprotein receptor-related protein 6, the accumulation of β-catenin, and the expression of vascular endothelial growth factor in vivo and in vitro.

Conclusions: Taken together, these results suggest that the soluble VLN is a negative regulator of the Wnt pathway and has antiangiogenic activities. Nanoparticle-mediated expression of VLN may thus represent a novel therapeutic approach to treat pathological ocular angiogenesis and potentially other vascular diseases affected by Wnt signaling.

Citing Articles

Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.

Qi Q, Su D, Zhuang S, Yao S, Heindl L, Fan X Adv Sci (Weinh). 2025; 12(6):e2407340.

PMID: 39755928 PMC: 11809354. DOI: 10.1002/advs.202407340.

Innovative Use of Nanomaterials in Treating Retinopathy of Prematurity.

Wu K, Wang X, Anderson M, Tran S Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459018 PMC: 11509985. DOI: 10.3390/ph17101377.

The evolving roles of Wnt signaling in stem cell proliferation and differentiation, the development of human diseases, and therapeutic opportunities.

Yu M, Qin K, Fan J, Zhao G, Zhao P, Zeng W Genes Dis. 2024; 11(3):101026.

PMID: 38292186 PMC: 10825312. DOI: 10.1016/j.gendis.2023.04.042.

Ocular Delivery of Therapeutic Proteins: A Review.

Shastri D, Silva A, Almeida H Pharmaceutics. 2023; 15(1).

PMID: 36678834 PMC: 9864358. DOI: 10.3390/pharmaceutics15010205.

An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.

Zhang C, Yin Y, Zhao J, Li Y, Wang Y, Zhang Z Int J Nanomedicine. 2022; 17:4911-4931.

PMID: 36267540 PMC: 9578304. DOI: 10.2147/IJN.S375570.

References

Lee K, Hu Y, Ding L, Chen Y, Takahashi Y, Mott R . Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. Diabetes. 2012; 61(11):2948-57. PMC: 3478529. DOI: 10.2337/db11-0300. View

Dorrell M, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J . Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest. 2009; 119(3):611-23. PMC: 2648679. DOI: 10.1172/JCI35977. View

Liu X, Lin Z, Zhou T, Zong R, He H, Liu Z . Anti-angiogenic and anti-inflammatory effects of SERPINA3K on corneal injury. PLoS One. 2011; 6(1):e16712. PMC: 3031620. DOI: 10.1371/journal.pone.0016712. View

Bunker D, George R, Kleinschmidt A, Kumar R, Maitz P . Alkali-related ocular burns: a case series and review. J Burn Care Res. 2013; 35(3):261-8. DOI: 10.1097/BCR.0b013e31829b0037. View

Gehrs K, Anderson D, Johnson L, Hageman G . Age-related macular degeneration--emerging pathogenetic and therapeutic concepts. Ann Med. 2006; 38(7):450-71. PMC: 4853957. DOI: 10.1080/07853890600946724. View

Cheng Z, Biechele T, Wei Z, Morrone S, Moon R, Wang L . Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat Struct Mol Biol. 2011; 18(11):1204-10. PMC: 3249237. DOI: 10.1038/nsmb.2139. View

Chen J, Stahl A, Krah N, Seaward M, Dennison R, Sapieha P . Wnt signaling mediates pathological vascular growth in proliferative retinopathy. Circulation. 2011; 124(17):1871-81. PMC: 3326389. DOI: 10.1161/CIRCULATIONAHA.111.040337. View

De Iongh R, Abud H, Hime G . WNT/Frizzled signaling in eye development and disease. Front Biosci. 2006; 11:2442-64. DOI: 10.2741/1982. View

Rathmann W, Giani G . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(10):2568-9. DOI: 10.2337/diacare.27.10.2568. View

10.

Reis M, Liebner S . Wnt signaling in the vasculature. Exp Cell Res. 2013; 319(9):1317-23. DOI: 10.1016/j.yexcr.2012.12.023. View

11.

Ishibashi S, Brown M, Goldstein J, Gerard R, Hammer R, Herz J . Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993; 92(2):883-93. PMC: 294927. DOI: 10.1172/JCI116663. View

12.

Kinnunen K, Yla-Herttuala S . Vascular endothelial growth factors in retinal and choroidal neovascular diseases. Ann Med. 2011; 44(1):1-17. DOI: 10.3109/07853890.2010.532150. View

13.

Park K, Chen Y, Hu Y, Mayo A, Kompella U, Longeras R . Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes. 2009; 58(8):1902-13. PMC: 2712783. DOI: 10.2337/db08-1327. View

14.

Liu X, Zhang B, McBride J, Zhou K, Lee K, Zhou Y . Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway. Diabetes. 2013; 62(12):4228-38. PMC: 3837048. DOI: 10.2337/db12-1710. View

15.

Panyam J, Zhou W, Prabha S, Sahoo S, Labhasetwar V . Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002; 16(10):1217-26. DOI: 10.1096/fj.02-0088com. View

16.

Jiang A, Hu W, Meng H, Gao H, Qiao X . Loss of VLDL receptor activates retinal vascular endothelial cells and promotes angiogenesis. Invest Ophthalmol Vis Sci. 2008; 50(2):844-50. DOI: 10.1167/iovs.08-2447. View

17.

Liu S, Liu Y, Yang X, Tong C, Edwards D, Parkin I . The Brassica oleracea genome reveals the asymmetrical evolution of polyploid genomes. Nat Commun. 2014; 5:3930. PMC: 4279128. DOI: 10.1038/ncomms4930. View

18.

Campochiaro P . Ocular neovascularization. J Mol Med (Berl). 2013; 91(3):311-21. PMC: 3584193. DOI: 10.1007/s00109-013-0993-5. View

19.

Dejana E . The role of wnt signaling in physiological and pathological angiogenesis. Circ Res. 2010; 107(8):943-52. DOI: 10.1161/CIRCRESAHA.110.223750. View

20.

Hu Y, Chen Y, Lin M, Lee K, Mott R, Ma J . Pathogenic role of the Wnt signaling pathway activation in laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci. 2012; 54(1):141-54. PMC: 3544418. DOI: 10.1167/iovs.12-10281. View